Meeting
2018 Gastrointestinal Cancers Symposium
Clinical outcomes of anti-EGFR antibody treatment for right-sided colon cancer patients without RAS, BRAF, and PIK3CA mutations in the later line.
Authors
Yuta Ushida
Japanese Foundation for Cancer Research, Tokyo, Japan
Yuta Ushida , Eiji Shinozaki , Keisho Chin , Mitsukuni Suenaga , Daisuke Takahari , Masato Ozaka , Mariko Ogura , Takashi Ichimura , Takeru Wakatsuki , TOMOHIRO MATSUSHIMA , Hiroki Osumi , Yumiko Ota , Kensei Yamaguchi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 812)
DOI
10.1200/JCO.2018.36.4_suppl.812
Abstract #
812
Poster Bd #
M11
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Identification of MAPK and mTOR pathway alterations in HER2-amplified colorectal cancer.
First Author: Svea Cheng
Poster
2017 Gastrointestinal Cancers Symposium
Relationship between tumor location and oncogenes mutations (RAS, BRAF, and PIK3CA) in colorectal cancer.
First Author: Daisuke Inagaki
Poster
2017 Gastrointestinal Cancers Symposium
Parallel sequencing of a 50 genes panel in metastatic colorectal cancer (MCRC) patients (pts) treated with intensive first-line FIr-B/FOx triplet chemotherapy plus bevacizumab (BEV): Preliminary data and clinical outcome.
First Author: Gemma Bruera
Poster
2016 ASCO Annual Meeting
Association of right-sided colon cancer with poor efficacy of cetuximab in patients with RAS wild-type metastatic colorectal cancer.
First Author: Dalyong Kim